AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39294033 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of carotid plaque (CP)
Number of subjects: 2419
Study 39294149 — intervention group
Group type: EXPERIMENTAL
Intervention: BWC0977 (Novel Bacterial Topoisomerase Inhibitor)
Number of subjects: 0
Study 39294181 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb (CS) application
Number of subjects: 16
Study 39294392 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' evaluations of SD-OCT scans
Number of subjects: 133
Study 39294392 — intervention group
Group type: COMPARATOR
Intervention: Reading centres (RCs) evaluations of SD-OCT scans
Number of subjects: 133
Study 39294392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ME cohort evaluations
Number of subjects: 133
Study 39294392 — intervention group
Group type: COMPARATOR
Intervention: Visits with RC-detected foveal IRF and/or SRF
Number of subjects: 133
Study 39294392 — intervention group
Group type: COMPARATOR
Intervention: Visits with foveal fluid
Number of subjects: 133
Study 39294392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall BCVA outcomes
Number of subjects: 133
Study 39294452 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (≥8 medications)
Number of subjects: 616
Study 39294452 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (≥1 PIM per STOPP)
Number of subjects: 616
Study 39294471 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) with a translocator protein radioligand
Number of subjects: 25
Study 39294471 — intervention group
Group type: COMPARATOR
Intervention: Conventional magnetic resonance imaging (MRI)
Number of subjects: 25
Study 39294522 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (10 or 18 mg)
Number of subjects: 40
Study 39294522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 39294600 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CT angiography
Number of subjects: 69
Study 39294600 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 69
Study 39294617 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission SBP ≤ 120 mmHg
Number of subjects: 3809
Study 39294617 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission SBP > 120 mmHg
Number of subjects: 3809
Study 39294617 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission SBP 121-150 mmHg
Number of subjects: 3809
Study 39294617 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≤ 120 mmHg in Killip class I-II
Number of subjects: 3809
Study 39294617 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission SBP above 120 mmHg
Number of subjects: 3809
Study 39294797 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave (ESW) therapy
Number of subjects: 60
Study 39294797 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 60
Study 39294797 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave (ESW) combined with PRP
Number of subjects: 60
Study 39294797 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 39294818 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (REM)
Number of subjects: 179
Study 39294818 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX)
Number of subjects: 179
Study 39295091 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke-side rowers
Number of subjects: 64
Study 39295091 — intervention group
Group type: COMPARATOR
Intervention: Non-rowing controls
Number of subjects: 64
Study 39295091 — intervention group
Group type: COMPARATOR
Intervention: Scull rowers
Number of subjects: 64
Study 39295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe stenosis (CSA values)
Number of subjects: 64
Study 39295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate stenosis (CSA values)
Number of subjects: 64
Study 39295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Average CSA
Number of subjects: 64
Study 39295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Radiculopathy Impact Scale
Number of subjects: 64
Study 39295627 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L General Quality of Life Scale
Number of subjects: 64
Study 39295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of cervical stenosis
Number of subjects: 64
Study 39295627 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck and arm pain, numbness, disability, and quality of life
Number of subjects: 64
Study 39296351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low, medium, and high-intensity aquatic physiotherapy protocols
Number of subjects: 15
Study 39296351 — intervention group
Group type: COMPARATOR
Intervention: Reference group (same aquatic physiotherapy protocols)
Number of subjects: 15
Study 39296821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-to-fast AS progression rate (median change in peak aortic jet velocity ≥0.11 m/s/year)
Number of subjects: 244
Study 39296821 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status decline during follow-up
Number of subjects: 244
Study 39296829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback-Assisted Mindfulness Training Program (NAMTP)
Number of subjects: 40
Study 39296829 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 39296832 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) at age 5.5 years
Number of subjects: 432
Study 39296832 — intervention group
Group type: EXPERIMENTAL
Intervention: Reallocating 30 minutes from MVPA to sleep
Number of subjects: 432
Study 39296832 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized PA/sports, outdoor play, and reading books
Number of subjects: 432
Study 39296832 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor play and screen-viewing
Number of subjects: 432
Study 39296855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 26
Study 39296855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 39296979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolgolimab 250 mg Q3W
Number of subjects: 114
Study 39296979 — intervention group
Group type: COMPARATOR
Intervention: Prolgolimab 1 mg/kg Q2W (historical control)
Number of subjects: 114
Study 39297052 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 7 mg/kg
Number of subjects: 21
Study 39297052 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab 10 mg/kg
Number of subjects: 21
Study 39297052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 39297416 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with distal median nerve block
Number of subjects: 118
Study 39297416 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 118
Study 39297486 — intervention group
Group type: EXPERIMENTAL
Intervention: High-EMST
Number of subjects: 31
Study 39297486 — intervention group
Group type: COMPARATOR
Intervention: Low-EMST
Number of subjects: 31
Study 39297486 — intervention group
Group type: EXPERIMENTAL
Intervention: EMST
Number of subjects: 31
Study 39297691 — intervention group
Group type: EXPERIMENTAL
Intervention: PanBio indirect dengue virus immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 770
Study 39297691 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IgG cut point
Number of subjects: 770
Study 39297691 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralization tests (PRNTs)
Number of subjects: 770
Study 39297691 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralization tests (PRNTs) with Zika, Japanese encephalitis, and West Nile viruses
Number of subjects: 770
Study 39297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary CPSP model
Number of subjects: 960
Study 39297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary threshold-based CPSP model
Number of subjects: 960
Study 39297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative threshold-based models
Number of subjects: 960
Study 39297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold-based models
Number of subjects: 960
Study 39297745 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors (Group A)
Number of subjects: 508
Study 39297745 — intervention group
Group type: COMPARATOR
Intervention: Mammalian target of rapamycin inhibitors (sirolimus - Group B)
Number of subjects: 508
Study 39297745 — intervention group
Group type: EXPERIMENTAL
Intervention: R3-AFP score
Number of subjects: 508
Study 39297745 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of the R3-AFP model
Number of subjects: 508
Study 39297834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 128
Study 39297834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 39297839 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day continuous electrocardiogram patch monitor
Number of subjects: 5684
Study 39297854 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 812
Study 39297855 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE CARDIOFORM ASD Occluder (GCA)
Number of subjects: 569
Study 39297940 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 313
Study 39297940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 39297964 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament threshold testing
Number of subjects: 142
Study 39297964 — intervention group
Group type: EXPERIMENTAL
Intervention: SPPB - Balance Subscale
Number of subjects: 142
Study 39298144 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) of 48 Gy in 4 fractions (peripheral NSCLC) or 60 Gy in 8 fractions (central NSCLC)
Number of subjects: 233
Study 39298144 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated conventional radiotherapy (CRT) of 60 Gy in 15 fractions
Number of subjects: 233
Study 39298144 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 233
Study 39298144 — intervention group
Group type: COMPARATOR
Intervention: SBRT and CRT
Number of subjects: 233
Study 39298147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rogaratinib 600 mg or 800 mg twice daily plus atezolizumab 1200 mg every 21 days
Number of subjects: 73
Study 39298147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rogaratinib plus atezolizumab
Number of subjects: 73
Study 39298170 — intervention group
Group type: EXPERIMENTAL
Intervention: WELL-B intervention (5 hours over 8 days)
Number of subjects: 643
Study 39298170 — intervention group
Group type: COMPARATOR
Intervention: Control group (received WELL-B after the end of the RCT)
Number of subjects: 643
Study 39298171 — intervention group
Group type: EXPERIMENTAL
Intervention: Static testing strategy (tests offered once every 2 weeks)
Number of subjects: 2389
Study 39298171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic testing strategy (tests offered once a week, once every 2 weeks, or once a month depending on county COVID-19 infection prevalence)
Number of subjects: 2389
Study 39298171 — intervention group
Group type: COMPARATOR
Intervention: Older patients (per 5-year age increment)
Number of subjects: 2389
Study 39298171 — intervention group
Group type: COMPARATOR
Intervention: Patients with diabetes vs without diabetes
Number of subjects: 2389
Study 39298171 — intervention group
Group type: COMPARATOR
Intervention: Women compared with men
Number of subjects: 2389
Study 39298171 — intervention group
Group type: COMPARATOR
Intervention: Hispanic patients compared with White patients
Number of subjects: 2389
Study 39298171 — intervention group
Group type: COMPARATOR
Intervention: Patients living in Republican-leaning zip codes compared to Democratic-leaning zip codes
Number of subjects: 2389
Study 39298511 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide poisoning
Number of subjects: 48600
Study 39298716 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (75 mg/m² orally once daily for 21 days of 28-day cycles)
Number of subjects: 23
Study 39298718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Radiation Therapy (RT)
Number of subjects: 66
Study 39298738 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted pretransplant regimen involving the anti-CD45 radioconjugate
Number of subjects: 153
Study 39298738 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 153
Study 39298750 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified web app (DuCATA_GAM-CaT)
Number of subjects: 74
Study 39298750 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive analysis techniques
Number of subjects: 74
Study 39298763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vira+Coaching
Number of subjects: 73
Study 39298763 — intervention group
Group type: COMPARATOR
Intervention: Vira Self-Care
Number of subjects: 73
Study 39298831 — intervention group
Group type: EXPERIMENTAL
Intervention: Good LIPI
Number of subjects: 153
Study 39298831 — intervention group
Group type: COMPARATOR
Intervention: Intermediate/Poor LIPI
Number of subjects: 153
Study 39298831 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently inter/poor LIPI
Number of subjects: 153
Study 39298831 — intervention group
Group type: COMPARATOR
Intervention: Persistently good LIPI
Number of subjects: 153
Study 39299058 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) group (n=94)
Number of subjects: 188
Study 39299058 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=94)
Number of subjects: 188
Study 39299389 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 40
Study 39299389 — intervention group
Group type: COMPARATOR
Intervention: Low Tidal Volume (LTV) Ventilation
Number of subjects: 40
Study 39299540 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestion index alerts
Number of subjects: 329
Study 39299540 — intervention group
Group type: COMPARATOR
Intervention: Standard weight rule
Number of subjects: 329
Study 39299543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting group (24-h fast one day per week for 12 weeks)
Number of subjects: 0
Study 39299543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting/weight maintenance group (24-h fast one day per week for 12 weeks)
Number of subjects: 0
Study 39299543 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39299543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting group
Number of subjects: 0
Study 39299544 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Resilience and Recovery Program (TRRP)
Number of subjects: 350
Study 39299544 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 350
Study 39299545 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Number of subjects: 247
Study 39299545 — intervention group
Group type: COMPARATOR
Intervention: Current Practice (CP)
Number of subjects: 247
Study 39299559 — intervention group
Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir co-administered with itraconazole (strong CYP3A and P-gp inhibitor)
Number of subjects: 0
Study 39299559 — intervention group
Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir co-administered with midazolam (CYP3A substrate)
Number of subjects: 0
Study 39299559 — intervention group
Group type: COMPARATOR
Intervention: Simnotrelvir/ritonavir alone
Number of subjects: 0
Study 39299559 — intervention group
Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir co-administered with rifampicin (strong CYP3A and P-gp inducer)
Number of subjects: 0
Study 39299591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanvello (digital mental health intervention) for 8 weeks
Number of subjects: 280
Study 39299591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanvello (digital mental health intervention)
Number of subjects: 280
Study 39299591 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 280
Study 39299726 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial signatures associated with SLE and IBD
Number of subjects: 6
Study 39299726 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive biomarkers from species profiles and functional genes
Number of subjects: 6
Study 39299726 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-protein interaction analyses
Number of subjects: 6
Study 39299726 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental validation of interactions
Number of subjects: 6
Study 39299726 — intervention group
Group type: EXPERIMENTAL
Intervention: Insights into therapeutic implications
Number of subjects: 6
Study 39299734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) started according to the '1-3-6-12 days rule' in 255 patients (39.2%).
Number of subjects: 708
Study 39299734 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K-dependent OAC started in 521 patients.
Number of subjects: 708
Study 39299734 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC restarted within 3 months of stroke/TIA.
Number of subjects: 708
Study 39300008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin maintenance infusion at 4.5 IU·hr
Number of subjects: 40
Study 39300008 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-IU oxytocin bolus followed by maintenance infusion
Number of subjects: 40
Study 39300055 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf Circumference (CC)
Number of subjects: 228
Study 39300055 — intervention group
Group type: EXPERIMENTAL
Intervention: SARC-F
Number of subjects: 228
Study 39300055 — intervention group
Group type: EXPERIMENTAL
Intervention: SARC-CalF
Number of subjects: 228
Study 39300055 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-adjusted CC
Number of subjects: 228
Study 39300077 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan HR070803 combined with 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 0
Study 39300077 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 39300222 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib 140 mg/day
Number of subjects: 1162
Study 39300222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 280 mg/day
Number of subjects: 1162
Study 39300222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg/day
Number of subjects: 1162
Study 39300222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/day
Number of subjects: 1162
Study 39300222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib >560 mg/day
Number of subjects: 1162
Study 39300222 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of IRAF reporting
Number of subjects: 1162
Study 39300290 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography screening
Number of subjects: 1201
Study 39300290 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1201
Study 39300320 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaglenastat (CB-839) combined with azacytidine (AZA)
Number of subjects: 30
Study 39300328 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perception measured using the Brief Illness Perception Questionnaire (BIPQ)
Number of subjects: 178
Study 39300328 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured using the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 178
Study 39300328 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety measured using the Generalized Anxiety Disorder-7 (GAD-7)
Number of subjects: 178
Study 39300328 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies measured using the Brief-COPE Scale
Number of subjects: 178
Study 39300328 — intervention group
Group type: EXPERIMENTAL
Intervention: AF symptoms measured using the Atrial Fibrillation Severity Scale (AFSS)
Number of subjects: 178
Study 39300363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (NEAR) combined with standard psychiatric rehabilitation, conducted three times a week for 12 weeks.
Number of subjects: 0
Study 39300363 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric rehabilitation only.
Number of subjects: 0
Study 39300364 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended postnatal prophylaxis (PNP) with lamivudine until end of follow-up or end of breastfeeding; all 18 infants eligible for PNP initiated on lamivudine.
Number of subjects: 102
Study 39300364 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care early infant diagnosis (EID) performed at EPI-2 (8 weeks).
Number of subjects: 102
Study 39300364 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretrovirals prescribed to all mothers.
Number of subjects: 102
Study 39300376 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) combined with Simvastatin (SIM) plus gemcitabine/nab-paclitaxel-based regimens (AG or PAXG)
Number of subjects: 240
Study 39300376 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (standard arm)
Number of subjects: 240
Study 39300414 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and Resources (E&R)
Number of subjects: 700
Study 39300414 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisectoral Community Collaborative Care (MCC)
Number of subjects: 700
Study 39300414 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC + Technology
Number of subjects: 700
Study 39300414 — intervention group
Group type: COMPARATOR
Intervention: E&R
Number of subjects: 700
Study 39300414 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC
Number of subjects: 700
Study 39300419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 75
Study 39300419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 75
Study 39300419 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 39300443 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-competing task intervention
Number of subjects: 144
Study 39300443 — intervention group
Group type: COMPARATOR
Intervention: Attention-based control task
Number of subjects: 144